
|Videos|October 30, 2017
Monitoring MRD in Patients with AML
Author(s)Richard M. Stone, MD
Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease (MRD) in patients with acute myeloid leukemia (AML).




















